Showing results (41-50 of 196) with videos related to
Sort By:
Pageof 20
Chemistry and Physics of Lipids|March 24, 2004
Determinants of F2-isoprostane biosynthesis and inhibition in manGiovanni Davì, Angela Falco, Carlo PatronoSeminars in Dialysis|November 10, 2007
Misleading associations between cholesterol and vascular outcomes in dialysis patients: the need for randomized trialsColin Baigent, Martin J Landray, David C WheelerBlood|January 22, 2013
Platelet activation and inhibition in polycythemia vera and essential thrombocythemiaCarlo Patrono, Bianca Rocca, Valerio De StefanoThe Lancet. Gastroenterology & Hepatology|February 25, 2018
Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trialsBenjamin Scally, Jonathan R Emberson, Enti Spata, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 21, 2014
Neprilysin inhibition in chronic kidney diseaseParminder Judge, Richard Haynes, Martin J Landray, et al.Nature Reviews. Clinical Oncology|April 5, 2012
The role of aspirin in cancer preventionMichael J Thun, Eric J Jacobs, Carlo PatronoJournal of the National Cancer Institute|February 21, 2002
Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issuesMichael J Thun, S Jane Henley, Carlo PatronoCardiovascular Research|January 23, 2021
The key contribution of platelet and vascular arachidonic acid metabolism to the pathophysiology of atherothrombosisLina Badimon, Gemma Vilahur, Bianca Rocca, et al.Seminars in Thrombosis and Hemostasis|May 5, 2006
Aspirin for the control of platelet activation and prevention of thrombosis in essential thrombocythemia and polycythemia vera: current insights and rationale for future studiesRaffaele Landolfi, Leonardo Di Gennaro, Linda Novarese, et al.Pharmacological Reviews|January 27, 2026
Platelet activation, aspirin, and cancer: From basic science to clinical trialsCarlo Patrono, John Burn, Paola Patrignani, et al.Pageof 20